Regeneron Pharmaceuticals (NASDAQ:REGN) & Capricor Therapeutics (NASDAQ:CAPR) Critical Comparison

Capricor Therapeutics (NASDAQ:CAPR) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.

Analyst Ratings

This is a summary of current recommendations and price targets for Capricor Therapeutics and Regeneron Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	0	0	2	0	3.00
Regeneron Pharmaceuticals	1	4	19	0	2.75

Capricor Therapeutics currently has a consensus target price of $16.50, suggesting a potential upside of 149.62%. Regeneron Pharmaceuticals has a consensus target price of $903.27, suggesting a potential upside of 8.61%. Given Capricor Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Capricor Therapeutics is more favorable than Regeneron Pharmaceuticals.

Institutional and Insider Ownership

10.2% of Capricor Therapeutics shares are held by institutional investors. Comparatively, 84.2% of Regeneron Pharmaceuticals shares are held by institutional investors. 12.5% of Capricor Therapeutics shares are held by company insiders. Comparatively, 8.8% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Capricor Therapeutics and Regeneron Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	$2.55 million	66.83	-$29.02 million	($1.17)	-5.65
Regeneron Pharmaceuticals	$12.17 billion	7.42	$4.34 billion	$37.83	21.98

Regeneron Pharmaceuticals has higher revenue and earnings than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Capricor Therapeutics has a beta of 3.88, indicating that its share price is 288% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500.

Profitability

This table compares Capricor Therapeutics and Regeneron Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	-309.05%	-323.39%	-57.33%
Regeneron Pharmaceuticals	33.93%	19.19%	14.94%

Summary

Regeneron Pharmaceuticals beats Capricor Therapeutics on 9 of the 14 factors compared between the two stocks.

About Capricor Therapeutics

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.